Week in Review: Teva Pays $160 Million for US/Canada Rights to Celltrion Biosimilars

Teva paid $160 million to partner with South Korea's Celltrion and commercialize two of Celltrion's biosimilar cancer drugs in the US and Canada; Enable Injections, a Cincinnati medical device maker, announced a $30 million A round funding led by ORI Healthcare Fund of Hong Kong; Emmaus Life Sciences of Los Angeles raised a net $6 million from Korean investors for its sickle cell disease product; HitGen, a Chengdu early-stage CRO, formed a global multi-target collaboration with Janssen Biotech to discover new candidates for oncology and metabolics targets; New Silkroutes Group of Singapore announced a private equity JV focused on healthcare investments in Asia Pacific; 80% of the applications for new drugs in China rely on compromised data, according to a CFDA investigation; WuXi AppTec, a China-US CRO/CMO, officially opened a 150,000-square-foot biomanufacturing facility in Philadelphia; Novartis announced it would close down its Shanghai biologics R&D operations, a small part of its new $1 billion Shanghai R&D center; TLC, a Taiwan novel drug developer, was approved to begin US trials of a generic oncology drug with a novel delivery system; and Ascentage Pharma's Shanghai Analytical Laboratory passed a certification test from the China National Accreditation Service. More details.... Stock Symbols: (KOSDAQ: 068270) (NYSE/TASE: TEVA) (NYSE: NVS) (TT: 4152) Share this with colleagues: // //